512 — Grand Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$14.36bn
- HK$15.42bn
- HK$10.53bn
- 59
- 88
- 47
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6,591 | 6,353 | 8,598 | 9,562 | 10,530 |
Cost of Revenue | |||||
Gross Profit | 4,041 | 4,035 | 5,247 | 5,951 | 6,524 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,203 | 4,226 | 5,833 | 6,864 | 7,955 |
Operating Profit | 1,388 | 2,127 | 2,765 | 2,698 | 2,574 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 1,356 | 2,074 | 2,786 | 2,517 | 2,344 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,125 | 1,781 | 2,405 | 2,098 | 1,895 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,151 | 1,793 | 2,403 | 2,079 | 1,880 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1,161 | 1,793 | 2,403 | 2,079 | 1,880 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.347 | 0.521 | 0.685 | 0.598 | 0.645 |
Dividends per Share |